Olpasiran trial to lower Lp(a) and prevent first heart attack or stroke
Part of Heart & circulation clinical trials.
This trial tests if olpasiran can lower a type of cholesterol called Lp(a) to help prevent a first major heart attack, stroke, or other heart problems. It is for people at higher risk due to risk factors or early signs of artery disease, but who have not yet had a heart attack or stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older.
- Your Lp(a) level must be 200 nmol/L or higher at screening.
- You must have multiple risk factors for heart disease (like diabetes, high blood pressure, smoking) or some evidence of artery narrowing.
- You cannot have had a previous heart attack, stroke, mini-stroke, or severe leg circulation problem.
- You cannot have had or be planning any artery-opening procedure (like stenting or bypass).
- You must not have a history of a serious bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a medication called olpasiran can lower a type of fat in your blood called Lp(a), which is linked to heart problems. You take the medicine or a placebo and get a special heart scan to see changes in your arteries.
This study tests a new medicine called muvalaplin that lowers a specific type of cholesterol linked to heart disease. It aims to see if muvalaplin can reduce the risk of future heart attacks, strokes, or related procedures in people with high levels of this cholesterol.
This program provides early access to a study drug called olpasiran, which may help lower cholesterol. Doctors can request it for patients who have no other treatment options and cannot join a clinical trial.
This study tests whether a new medicine called lepodisiran can shrink plaque in heart arteries for adults with high Lp(a) (a type of cholesterol linked to heart disease) who have had a heart event or are at serious risk. The trial uses CT scans to monitor changes in your arteries.
This study looks at levels of a type of cholesterol called Lp(a) in people with certain heart and blood vessel diseases. The goal is to understand how common high Lp(a) is in Russian adults with these conditions.
This study tests an oral medication called HRS-5346 to see if it can lower a type of fat in the blood called lipoprotein(a), which is linked to heart disease. If you have high Lp(a) and are at risk for heart problems, this trial may help reduce that risk.
Hear when a new Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.